Navigation Links
HemoShear to Develop Human Cancer Models to Improve Industry Success Rates in New Anticancer Drug Development
Date:11/7/2013

CHARLOTTESVILLE, Va., Nov. 7, 2013 /PRNewswire/ -- Safer and more effective anticancer drugs may soon be developed thanks to a Small Business Innovation Research contract recently awarded to HemoShear by the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH).  HemoShear, LLC, is the pharmaceutical industry's leading developer of the most advanced human biology systems for applications in drug research and development. 

(Logo: http://photos.prnewswire.com/prnh/20120416/PH86899LOGO)

Anticancer drugs continue to suffer the highest rate of failure in clinical trials as compared with other therapeutic areas.  According to the NCI, "There is a critical need to improve the accuracy of preclinical drug efficacy screening and testing through the development of [laboratory-based] culture systems that more effectively mimic the [human] environment.  Systems to properly recreate the tumor microenvironment are lacking and [are] essential to advance the discovery and development of effective anticancer agents."

HemoShear's contract with the National Cancer Institute will support the development of human cell-based systems that accurately replicate the biology of lung and pancreatic tumors, two of the deadliest groups of tumors.  "Lung and pancreatic cancer are terrible diseases that have no effective treatments," said Dr. Brian Wamhoff, HemoShear co-founder and Vice President of R&D.  "We are using our innovative science to enable the discovery of new treatments for cancer patients.  While billions of dollars continue to be spent on researching and developing new cancer therapies, their success rates in clinical trials are not improving.  Imagine a human tumor on the laboratory bench that responds to new therapies as if it were in the human body.  That is what our science is capable of achieving," said Dr. Wamhoff.

HemoShear's success in this initial stage of tumor system development will lead to development of other cancer tumor systems, to systems that replicate metastasis and potentially to new treatments for patient-specific tumors. 

"This is HemoShear's third major area of SBIR funding from separate divisions of the NIH in three years.  We are grateful for the strong support of NIH and the scientific community.  We believe that HemoShear science will yield safer and more effective therapies while avoiding costly new drug failures," said Jim Powers, HemoShear's CEO.

About HemoShear

HemoShear has developed the only technology of its kind that accurately replicates human organ system and disease biology in the laboratory.  HemoShear science is rapidly being adopted by leading pharmaceutical and biotechnology companies to make better decisions and select drug candidates with superior efficacy and safety profiles.  Working in partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making and reduce risk of costly failures.


'/>"/>
SOURCE HemoShear, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. HemoShear Hires Industry Business Development Veteran Vincent Aurentz as Chief Business Officer
2. HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database
3. HemoShear to Present at Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Conference
4. Cato Research Presents at Korea-Maryland, USA BIO EXPO, Drug Development Process and Regulatory Approaches
5. Novogen Launches Joint Venture Aimed At Developing Drugs to Fight Ovarian Cancer
6. Tunisia Hosts First African Summer School on Optics and Applications to Sustainable Development
7. Rancho BioSciences Will Present the Accelerated Cure Project Multiple Sclerosis Data Curation White Paper at the tranSMART Fall Developers Meeting, Paris, November 5-7
8. Clinical Research Site-Expert Johan Karlberg to Lead ACRES Global Network Development
9. Global Sports Development's Symposium on Doping Deepens the Anti-Doping Discussion
10. Cytos Biotechnology Ltd Reports Third Quarter 2013 Financial Results and Recent Developments
11. Biomarker Challenges in Biosimilar Drug Development, New Life Science Webinar Hosted by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
Breaking Biology News(10 mins):